IGC 1C
Alternative Names: IGC-1CLatest Information Update: 27 Aug 2024
Price :
$50 *
At a glance
- Originator India Globalization Capital
- Class Antidementias; Peptides; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 23 Aug 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by India Globalization Capital
- 06 Dec 2023 India Globalization Capital collaborates with Center for research and formation in artificial intelligence to leverage generative AI in clinical development of IGC 1C
- 21 Nov 2023 India Globalization Capital has patents pending entitled "Method and composition for treating CNS disorders" worldwide